Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Amphastar posts record Q3 revenue and profit, driven by BAQSIMI and Primatene MIST sales.

What the company is saying

Amphastar Pharmaceuticals, Inc. reports net revenues of $207.6 million and GAAP net income of $37.8 million ($0.87 per share) for Q3 2026, highlighting these as record results. The company attributes revenue growth to strong sales of BAQSIMI ($58.8 million) and Primatene MIST ($31.5 million), as well as contributions from new product launches. CEO Dr. Jack Zhang frames the quarter as validation of the company’s diversified portfolio and commercial platform, emphasizing continued investment in manufacturing, quality, and development capabilities to support future growth. The announcement details product-level revenue drivers, noting that BAQSIMI growth was primarily volume-driven but partially offset by lower average selling prices, while Primatene MIST benefited from both price increases and higher volumes. The company also draws attention to its pipeline, referencing FDA filings and development programs targeting large market opportunities, though without providing specific regulatory milestones or timelines. Amphastar’s board has authorized a $50 million increase to its share buyback program, with the stated goal of offsetting equity compensation dilution.

What the data suggests

The disclosed figures show Q3 net revenues of $207.6 million, up 8% year-over-year, and GAAP net income of $37.8 million, with adjusted non-GAAP net income at $49.3 million. Gross profit for the quarter was $99.6 million, representing a gross margin of 48.0%, down from 51.4% in Q3 2025, due to lower average selling prices for key products and increased manufacturing expenses tied to remediation and facility expansion. BAQSIMI sales rose by $5.2 million (10%), with $7.4 million attributed to higher volumes and a $2.2 million offset from pricing. Primatene MIST grew by $2.7 million (9%), split between a $1.6 million price increase and $1.0 million volume growth. Lidocaine sales increased by $3.7 million (29%) due to supplier shortages, while new launches like ipratropium bromide contributed $6.6 million. Epinephrine and glucagon sales declined, primarily from lower volumes and increased competition, respectively. Operating expenses were stable or down, with G&A dropping by $22.6 million due to the absence of a prior-year litigation provision. Cash flow from operations for the nine months was $142.5 million. The company’s pipeline targets markets exceeding $6.3 billion in aggregate, but no new regulatory or commercial milestones are disclosed. The buyback program expansion is confirmed but actual repurchase timing and amounts remain unspecified.

Analysis

The announcement provides detailed, realised financial results for the quarter and year-to-date, including net revenues, GAAP and non-GAAP net income, EPS, gross profit, and cash flow from operations. These are supported by product-level sales data and year-over-year growth rates, demonstrating measurable operational and financial progress. While the release references pipeline products and large target markets, these forward-looking statements are clearly separated from the realised results and do not dominate the narrative. The tone is positive but proportionate to the evidence, with no exaggerated claims about future performance or imminent breakthroughs. Capital investments and pipeline ambitions are mentioned, but there is no indication of a large, immediate capital outlay with only long-dated, uncertain returns. The majority of key claims are realised facts, and the forward-looking elements are typical for a quarterly update.

Risk flags

• ●Gross margin compression is evident, falling from 51.4% to 48.0% year-over-year, driven by lower selling prices for high-margin products and increased manufacturing costs from remediation and facility expansion. If these trends persist, future profitability could be pressured even if top-line growth continues.
• ●Product concentration risk remains, as BAQSIMI and Primatene MIST together account for a significant share of revenue growth. Any disruption in these products’ demand, pricing, or regulatory status could materially impact results.
• ●Pipeline disclosures reference large target markets but lack detail on regulatory progress, timelines, or likelihood of approval, making future revenue contributions from these assets highly uncertain.
• ●Remediation efforts at the IMS facility, triggered by an FDA warning letter, have already slowed epinephrine product releases and increased costs. Delays or further regulatory actions could affect supply and profitability.
• ●The expanded share buyback program is discretionary and may not be fully executed if market or regulatory conditions change, so its impact on dilution and shareholder value is not guaranteed.

Bottom line

Amphastar delivered record Q3 revenue and profit, with strong sales from BAQSIMI and Primatene MIST offsetting declines in epinephrine and glucagon. Gross margin slipped due to pricing and manufacturing headwinds, but overall cash generation remains robust at $142.5 million for the year to date. The company’s pipeline targets large addressable markets, but with no new regulatory milestones or launch timelines, these remain long-term opportunities rather than immediate catalysts. The $50 million buyback program expansion signals confidence but is open-ended and subject to execution risk. Investors should focus on margin trends, resolution of IMS facility remediation, and tangible progress on pipeline assets to assess sustainability. The most important takeaway is that Amphastar’s current financial performance is solid, but future upside depends on margin recovery and pipeline execution.

Announcement summary

(NASDAQ:AMPH) Amphastar Pharmaceuticals, Inc. reported net revenues of $207.6 million for the three months ended September 30, 2026. GAAP net income for the third quarter was $37.8 million, or $0.87 per share. Adjusted non-GAAP net income for the third quarter was $49.3 million, or $1.14 per share. For the nine months ended September 30, 2026, net revenues were $562,682,000 and GAAP net income was $74,531,000. Adjusted non-GAAP net income for the nine months was $109,502,000. GAAP diluted EPS for the nine months was $1.67, and adjusted non-GAAP diluted EPS was $2.45. Third quarter net revenues by product included BAQSIMI® at $58,804,000, Primatene MIST® at $31,461,000, Lidocaine at $16,638,000, Epinephrine at $15,273,000, Glucagon at $8,575,000, Ipratropium bromide at $6,645,000, and other products at $70,212,000. BAQSIMI® sales increased by $5,196,000 (10%) year-over-year, primarily due to higher unit volumes, with $7.4 million in sales from marketing efforts, partially offset by a $2.2 million impact from lower average selling price. Primatene MIST® sales rose by $2,653,000 (9%), with $1.6 million from a price increase and $1.0 million from higher unit volumes. Lidocaine sales increased by $3,706,000 (29%) due to higher demand from supplier shortages. Ipratropium bromide sales were $6,645,000 following its launch in Q2 2026. Epinephrine sales decreased by $3,516,000 (19%) due to lower unit volumes from slower product releases at International Medication Systems, Limited (IMS). Glucagon sales fell by $4,983,000 (37%) due to increased competition. Other product sales increased, including teriparatide at $6.4 million (launched December 2025) and API sales from Amphastar Nanjing Pharmaceuticals, Inc. (ANP) at $6.2 million. Total net revenues increased by $15,768,000 (8%) compared to Q3 2025. Cost of revenues for the quarter was $107,979,000, up $14,785,000 (16%), resulting in gross profit of $99,629,000 (48.0% of net revenues). Selling, distribution, and marketing expenses were $11,934,000, general and administrative expenses were $16,844,000, and research and development expenses were $20,078,000. Non-operating expenses, net, were $(1,709,000), reflecting foreign currency fluctuations and mark-to-market adjustments on interest rate swaps. Cash flow from operating activities for the nine months ended September 30, 2026, was $142.5 million. On November 4, 2026, the Board authorized a $50 million increase to the share buyback program, which is expected to continue indefinitely to offset dilution from equity compensation. The company has one ANDA and one biosimilar insulin candidate filed with the FDA targeting a combined market size over $1.6 billion, two biosimilar products in development targeting over $3.5 billion, and three generic products in development targeting over $1.2 billion. The proprietary pipeline includes four in-licensed products (three peptides for oncology and ophthalmology, and a synthetic corticotropin compound for inflammatory and autoimmune conditions). Dr. Jack Zhang, President and CEO, stated that record sales of BAQSIMI® and Primatene MIST®, along with new product launches, supported revenue growth and the company's long-term strategy. The company continues to invest in manufacturing, quality, and development capabilities. Amphastar will hold a conference call on November 5, 2026, at 2:00 p.m. Pacific Time to discuss these results.

Disagree with this article?